

Screening for Familial Hypercholesterolemia: School Based Programs May Be Best Alternative

Gary Luckasen, MD; NaNet Jenkins, MPH, MHSA; Austin Pollack, MS; Landon D. Hamilton, PhD; Meghan Willis, MPH; Paige Lueders, BS

Introduction


- Familial Hypercholesterolemia (FH) is a heterozygous autosomal dominant condition characterized by elevated cholesterol and premature development of cardiovascular (CV) disease affecting 1/200 - 1/500 individuals.
- Only 10% of the affected population in the United States have been identified and treated compared to 50-70% in Scandinavian countries identified through school-based screening programs.
- If left untreated, CV disease occurs approximately 10 years earlier which results in increased mortality, disability, and health care costs.

Methods

- The UHealth Healthy Hearts and Minds Program (HHM) performs free biometric screenings on 5th, 7th, and 10th grade students in northern Colorado.
- HHM tested 10,991 5th grade students (9/2017 - 5/2022) and identified 424 students with total cholesterol levels ≥ 200 mg/dL (range 200-302).
- A buccal smear test (APOB, LDLR, PCSK9) was performed on 99 individuals with the highest total cholesterol levels prioritized (52% male, 10.6 years, 19.6 BMI).
- Binomial logistic regression model used for analysis.

Results

- Of the 99 students, six tested positive for FH (50% male, 10.3 years, 22.8 BMI) and five reported a variant of indeterminate significance (40% male, 11.3 years, 17.3 BMI).
- A sigmoidal association between total cholesterol and predicted chance of FH was identified with the inflection point at ~270 mg/dL.



These results further define the relation between total cholesterol and predicted chance of FH for a school-aged population where 245 mg/dL indicates a ~10% of testing positive for FH whereas 275 mg/dL has a ~55% chance.

Discussion

- The individual benefit of identifying FH early is the treatability of this condition. Early use of lipid lowering agents can make the CV disease risk equal to the general population.
- If elevated cholesterol is present in school aged children, genetic testing is warranted and treatment considered by age 8-10 years, especially if signs of abnormal vascular plaquing are identified.
- The multiplier effect documented through cascade FH testing enhances the benefit to other family members, as the autosomal dominant pattern ensures that 50% of members will be at risk.

Conclusions

- School based programs are the most effective and equitable means of identifying FH and should be supported in a collaborative manner with health care systems, industry, and the community.
- With availability to all students, diversity, equity, and inclusion concerns are addressed and provide at risk populations with personalized health information.
- The results from this study suggest school-based screening programs are the best mechanism for FH screening.

Acknowledgements: Invitae (Invitae Corporation, San Francisco, CA) provided genetic testing and counseling and was not involved in the study design, analysis, and interpretation of the data. We would like to thank the HHM staff for organizing the data collection as well as the participating schools and school districts.

Disclosures: None

uhealth